心血管の共同研究・ライセンシング契約（2016年～2025年）

当レポートでは、世界のバイオ医薬品業界について調査分析し、2016年～2025年の心血管の共同研究・ライセンシング契約589件に関する、契約条件などの詳細なデータを提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 心血管契約の動向

• イントロダクション
• 過去数年の心血管パートナー契約
• 心血管パートナー契約：契約タイプ別
• 心血管パートナー契約：産業部門別
• 心血管パートナー契約：開発段階別
• 心血管パートナー契約：技術タイプ別
• 心血管パートナー契約：適応症別

第3章 心血管パートナー契約に関する財務的契約条件

• イントロダクション
• 心血管パートナー契約に関する公開された財務条件
• 心血管パートナー契約のヘッドライン金額
• 心血管契約の前払い
• 心血管契約のマイルストーン払い
• 心血管のロイヤルティ率

第4章 主な心血管契約と交渉者

• イントロダクション
• 心血管パートナー契約においてもっとも活発
• 心血管分野においてもっとも活発な交渉者のリスト
• 上位の心血管契約（金額）

第5章 心血管契約文書ディレクトリ

• イントロダクション
• 契約書が入手可能な心血管パートナー契約

第6章 心血管契約：治療標的別

• イントロダクション
• 契約：心血管治療標的別
• 契約ディレクトリ
• 契約ディレクトリ - 心血管契約：企業別（A～Z）（2016年～2025年）
• 契約ディレクトリ - 心血管契約：技術タイプ別（2016年～2025年）
• 契約タイプの定義
• Biopharma Research Ltdについて
• Current Partnering
• Current Agreements
• Current Partneringからの近年のレポートのタイトル

Cardiovascular Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cardiovascular deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 589 cardiovascular deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of cardiovascular deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cardiovascular Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cardiovascular collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cardiovascular Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cardiovascular trends and structure of deals entered into by leading biopharma companies worldwide.

Cardiovascular Collaboration and Licensing Deals includes:

• Trends in cardiovascular dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of cardiovascular deal records covering pharmaceutical and biotechnology
• The leading cardiovascular deals by value
• Most active cardiovascular licensing dealmakers

In Cardiovascular Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Cardiovascular Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

• 2.1. Introduction
• 2.2. Cardiovascular partnering over the years
• 2.3. Cardiovascular partnering by deal type
• 2.4. Cardiovascular partnering by industry sector
• 2.5. Cardiovascular partnering by stage of development
• 2.6. Cardiovascular partnering by technology type
• 2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 - Financial deal terms for cardiovascular partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for cardiovascular partnering
• 3.3. Cardiovascular partnering headline values
• 3.4. Cardiovascular deal upfront payments
• 3.5. Cardiovascular deal milestone payments
• 3.6. Cardiovascular royalty rates

Chapter 4 - Leading cardiovascular deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in cardiovascular partnering
• 4.3. List of most active dealmakers in cardiovascular
• 4.4. Top cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory

• 5.1. Introduction
• 5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by cardiovascular therapeutic target
• Deal directory
• Deal directory - Cardiovascular deals by company A-Z 2016 to 2025
• Deal directory - Cardiovascular deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cardiovascular partnering since 2016
• Figure 2: Cardiovascular partnering by deal type since 2016
• Figure 3: Cardiovascular partnering by industry sector since 2016
• Figure 4: Cardiovascular partnering by stage of development since 2016
• Figure 5: Cardiovascular partnering by technology type since 2016
• Figure 6: Cardiovascular partnering by indication since 2016
• Figure 7: Cardiovascular deals with a headline value
• Figure 8: Cardiovascular deals with upfront payment values
• Figure 9: Cardiovascular deals with milestone payment
• Figure 10: Cardiovascular deals with royalty rates
• Figure 11: Active cardiovascular dealmaking activity since 2016
• Figure 12: Top cardiovascular deals by value since 2016